Compare Recursion Pharmaceuticals Inc (RXRX) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Schwab US Large Cap Growth ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.3 (market cap $1.81B), while Schwab US Large Cap Growth ETF trades at $35.62. The key difference: Schwab US Large Cap Growth ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | SCHG | |
|---|---|---|
Market Cap | $1.81B | — |
Sector | Health | Sector/Thematic |
52-Week High | $6.79 | $35.83 |
52-Week Low | $2.84 | $28.10 |
Enterprise Value | $1.33B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
SCHG trades at $35.63, down 0.56% today, with a bullish technical outlook driven by strong moving average signals. The ETF's concentrated exposure to AI leaders like Nvidia and Microsoft positions it for growth, though high RSI readings suggest potential near-term consolidation. Recent news highlights institutional activity and the fund's low 0.04% expense ratio as key advantages.
The outlook remains positive given SCHG's alignment with AI infrastructure growth, but risks include heavy tech concentration and sensitivity to interest rates. Wall Street sentiment is mixed, with some analysts citing valuation concerns while others emphasize long-term growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
